It may not be the time to sell them just yet, either, but the risks of staying aggressively long make this trader increasingly uncomfortable.
The biopharmaceutical company could offer a buying opportunity on a pullback based on its chart.
The stock has surged amid an analyst upgrade.
The stock just tested the underside of the declining 50-day moving average.
Here's what the longer-term picture looks like.
The shares gapped lower as the chicken supplier reported quarterly numbers. Let's check the charts.
Let's look at the charts and indicators.
While a near-term pause may be in the cards, improvements in trend and breadth are encouraging.
We know the federal government will be a buyer, as will the private sector, but there are challenges in this environment.
We could see some further price recovery in the short-run.